Patients receiving TNF inhibitors have reported increased rates of upper respiratory tract infections, pharyngitis, sinusitis, and rhinitis; moreover, cases of tuberculosis have emerged during clinical trials of TNF inhibitors. The gene discussed is TNF; the disease is rhinitis.